Documentation should include both objective measurements and subjective observations
All gastrointestinal adverse events (GI AEs) were mild, except for one participant who reported two moderate events (nausea and vomiting) and discontinued treatment after the third administration
Don't ask me about it, but like, there are these research chemicals which are available, like, I don't know, like it's all very legally, it's very gray
Moreover, BPC 157 therapy generated from its distinctive healing effects in various tissues also functions as an eye drops therapy that heals perforating corneal ulcers in rats and rapidly regains corneal transparency (Figures 14, 15) (Masnec et al., 2015)
GC-MS testing helps detect these residues
From these results BPC 157 shows a particular angiogenic/angiomodulatory potential, worthy of further investigation